NeuVasQ is a spin-off company from the University of Brussels aiming to repair neurovascular function in a range of disorders by restoring the integrity of the blood-brain barrier. The blood-brain barrier (BBB) regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in […]

View post to subscribe to site newsletter.

Tribune Therapeutics is a pre-clinical stage biopharmaceutical company developing novel biological drugs to treat patients with fibrotic diseases, including diseases affecting the kidney, lung and liver. Based on research from Håvard Attramadal‘s lab at Oslo University Hospital, Tribune’s medicines target the CCN protein family. The CCN protein family is a group of signalling proteins central […]

View post to subscribe to site newsletter.

xFOREST Therapeutics is a Japanese startup developing a platform for targeting disease-related RNA structures with small molecules. The company’s platform enables the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs. Tens of thousands of RNAs and tens of thousands of compounds from libraries can be analyzed in parallel with […]

View post to subscribe to site newsletter.